- CompletedPhase IV
ASCEND PLUS - a research study to test whether a treatment called oral semaglutide can protect people with type 2 diabetes from heart attacks, strokes, and other health problems
The ASCEND PLUS study tests whether a daily tablet called semaglutide can protect people with type 2 diabetes from heart attacks and strokes. It is open to UK adults aged 55 and older who have never had a heart attack or stroke. Everything is conveniently done from home.
For: Type 2 diabetesUnited Kingdom · England - RecruitingPHASE3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
This study compares a new medicine, Elecoglipron, to an existing one, Semaglutide, for adults with Type 2 Diabetes. It aims to see if the new drug is safe and effective for people whose diabetes isn't well-controlled and who have a higher risk of heart problems.
For: Type 2 Diabetes MellitusUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
This study is looking at a new medicine called Ribupatide for people living with obesity. It compares Ribupatide with another medicine, Semaglutide, and a dummy treatment, to see how well it helps with weight loss. We want to find out if Ribupatide is more effective and safe.
For: ObesityUnited States · Australia · Bulgaria - RecruitingTherapeutic use (Phase IV)
Young adults with early-onset obesity treated with semaglutide -The RESETTLE study - a randomized double blind placebo-controlled clinical trial
This study, called RESETTLE, is looking at how a medicine called semaglutide helps young adults with obesity. It compares semaglutide to a dummy medicine to see if it makes a difference to their weight and overall health.
For: ObesityDenmark - Active not recruitingPHASE3
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is looking at a medicine called semaglutide for a liver condition called non-alcoholic steatohepatitis (NASH). Participants will receive either semaglutide or a dummy medicine. It's a long study, lasting about 5 years, with regular clinic visits.
For: Non-alcoholic SteatohepatitisUnited States · Argentina · Australia - AuthorisedTherapeutic confirmatory (Phase III)
The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients
This study looks at how a medicine called semaglutide affects fat in the liver of men with obesity and a condition called MASLD. We want to see if it reduces liver fat and how the liver responds to fatty foods after taking the medicine.
For: ObesityCzechia - Active not recruitingPHASE4
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
This study looks at how a weekly injection, semaglutide, helps teenagers aged 12-15 with obesity to lose weight and keep it off. All participants will receive the treatment for at least three years, aiming to understand its effectiveness for weight management.
For: ObesityUnited States · Belgium · Canada - Active not recruitingPHASE1
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
This study is testing a new medicine, NNC0194-0499, for people with type 1 diabetes. Researchers want to see how it affects blood sugar when taken alone or with semaglutide, alongside your usual insulin.
For: Diabetes Mellitus, Type 1Germany - Active not recruitingPHASE3
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study looks at how a new medicine called CagriSema helps people who are overweight lose weight. It compares CagriSema to other medicines and a dummy medicine. Participants will take a weekly injection, and the study will last about 3 and a half years.
For: ObesityUnited States · Argentina · Australia - Active not recruitingPHASE3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study looks at how a medicine called semaglutide helps children and teenagers lose weight. Participants get weekly injections of either semaglutide or a dummy medicine. All also receive healthy lifestyle advice. The study lasts about 2.5 years.
For: ObesityUnited States · Austria · Belgium - Active not recruitingPHASE3
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
This study investigates how a medicine called semaglutide affects eye problems in people with type 2 diabetes over five years. Participants will get either semaglutide or a dummy medicine, injected once a week, along with their usual diabetes treatments.
For: Diabetes Mellitus, Type 2United States · Brazil · Bulgaria - RecruitingPHASE3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This study looks at new and existing medicines (CagriSema and Semaglutide) to help people with obesity, sometimes with type 2 diabetes, lose weight. Researchers want to see how safe and effective these medicines are. It lasts about 83 weeks.
For: Obesity · Type 2 DiabetesUnited States · Argentina · Australia - Active not recruitingPHASE3
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
This study is looking at a new medicine called CagriSema to help people with obesity lose weight. It compares CagriSema to a dummy medicine over three years. Participants won't know if they're getting the active medicine or the dummy medicine. The aim is to see how well it works long-term.
For: ObesityUnited States · Belgium · Canada - RecruitingPHASE2
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
This study looks at how a new drug, semaglutide, affects kidney health in adults with Type 1 diabetes. Researchers want to see if it can protect kidneys, improve their function, and help manage blood sugar, compared to a dummy drug.
For: Diabetic Kidney Disease · Type 1 DiabetesUnited States · Canada - Active not recruitingPHASE3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
This study looks at a new medicine called CagriSema to see how well it lowers blood sugar and helps with weight loss in people with type 2 diabetes. It's compared to another medicine called tirzepatide. Participants will get one of the medicines by chance.
For: Diabetes Mellitus, Type 2United States · Argentina · Australia - Active not recruitingNA
Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity
This study looks at whether the drug semaglutide can help people with schizophrenia spectrum disorders who are overweight or obese to lose weight. These individuals are also taking antipsychotic medications and haven't had good results with other weight loss treatments like metformin.
For: Schizophrenia Spectrum DisordersCanada - Active not recruitingPHASE3
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
This study compares two medicines, retatrutide and semaglutide, for adults with Type 2 Diabetes whose current treatment isn't enough. It will check how well they work and if they are safe, aiming to improve blood sugar control.
For: Diabetes Mellitus, Type 2United States · Argentina · Canada - Not yet recruitingPHASE4
DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies
This study looks at how new weight loss drugs, semaglutide and tirzepatide, affect blood vessels and blood pressure. Researchers want to understand if these drugs have direct benefits on the heart and blood system, beyond just helping people lose weight.
For: Cardiovascular DiseasesUnited Kingdom - Active not recruitingPHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.
For: Cardiovascular DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
This study looks at new treatments, CagriSema and cagrilintide, for children and teenagers aged 8-18 who are overweight. It compares these new drugs to an existing medicine (semaglutide) or a dummy drug (placebo) to see how well they help with weight loss.
For: Overweight · ObesityUnited States · Australia · Austria - Enrolling by invitation
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice
This study looks at how a medicine called Wegovy (semaglutide) is used in real life to help people with obesity. It will follow participants for two years to see how it affects weight, body size, and quality of life.
For: ObesitySpain · Switzerland · United Kingdom - Recruiting
Weight Loss in Adults Using Semaglutide (Real-world Study)
This study looks at how a medicine called semaglutide helps adults lose weight in real-life settings. Doctors decide who receives the treatment. It aims to see how effective semaglutide is for people who are overweight or obese, following their usual healthcare.
For: Overweight · ObesityUnited States · United Kingdom